123 related articles for article (PubMed ID: 38274372)
1. Co-alteration of Myc and RTK-RAS pathways defines a liver-metastatic propensity and immune-cold subgroup of pancreatic adenocarcinoma.
Zhang Y; Zu Z; Xu H; Weng S; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
Genes Dis; 2024 May; 11(3):100993. PubMed ID: 38274372
[No Abstract] [Full Text] [Related]
2. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
3. Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma.
Yin XQ; Yin XH; Yu YQ; Xu L; Zhang M
Front Oncol; 2022; 12():924239. PubMed ID: 35936718
[TBL] [Abstract][Full Text] [Related]
4. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
[TBL] [Abstract][Full Text] [Related]
5.
Maddipati R; Norgard RJ; Baslan T; Rathi KS; Zhang A; Saeid A; Higashihara T; Wu F; Kumar A; Annamalai V; Bhattacharya S; Raman P; Adkisson CA; Pitarresi JR; Wengyn MD; Yamazoe T; Li J; Balli D; LaRiviere MJ; Ngo TC; Folkert IW; Millstein ID; Bermeo J; Carpenter EL; McAuliffe JC; Oktay MH; Brekken RA; Lowe SW; Iacobuzio-Donahue CA; Notta F; Stanger BZ
Cancer Discov; 2022 Feb; 12(2):542-561. PubMed ID: 34551968
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation.
Yamada H; Yoshida T; Sakamoto H; Terada M; Sugimura T
Biochem Biophys Res Commun; 1986 Oct; 140(1):167-73. PubMed ID: 3778442
[TBL] [Abstract][Full Text] [Related]
7. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
8. Amplification, expression and localization of the c-myc gene in BSp73 rat tumor cell lines.
Birnbaum M; Spiess E
Anticancer Res; 1988; 8(6):1185-91. PubMed ID: 2464334
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
[TBL] [Abstract][Full Text] [Related]
10. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
12. Analysis of K-ras gene mutations in rare pancreatic and ampullary tumours.
Ebert MP; Hoffmann J; Schneider-Stock R; Kasper HU; Schulz HU; Lippert H; Roessner A; Malfertheiner P
Eur J Gastroenterol Hepatol; 1998 Dec; 10(12):1025-9. PubMed ID: 9895049
[TBL] [Abstract][Full Text] [Related]
13. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
14. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.
Schleger C; Verbeke C; Hildenbrand R; Zentgraf H; Bleyl U
Mod Pathol; 2002 Apr; 15(4):462-9. PubMed ID: 11950922
[TBL] [Abstract][Full Text] [Related]
15. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues.
Tiniakos D; Spandidos DA; Kakkanas A; Pintzas A; Pollice L; Tiniakos G
Anticancer Res; 1989; 9(3):715-21. PubMed ID: 2548435
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules.
Yu F; Peng M; Bai J; Zhu X; Zhang B; Tang J; Liu W; Chen C; Wang X; Chen M; Tan S; Sun Y; Liang Q; Li J; Hu Y; Liao A; Hu H; He Y; Xiao X; Wang B; Xing G; Xu Y; Chen R; Xia X; Chen X
Int J Cancer; 2022 Dec; 151(11):2020-2030. PubMed ID: 36029220
[TBL] [Abstract][Full Text] [Related]
17. Involvement of ERK1/2 signaling in proliferation of eight liver cell types during hepatic regeneration in rats.
Chen XG; Xu CS; Liu YM
Genet Mol Res; 2013 Mar; 12(1):665-77. PubMed ID: 23546948
[TBL] [Abstract][Full Text] [Related]
18. ras and myc analysis in primary and metastatic colorectal carcinomas.
Albanese I; Rinaudo C; Alberti M; Bazan V; Russo A; Migliavacca M; Bazan P; Dardanoni G; Tomasino R; Lafarina M
Int J Oncol; 1997 Feb; 10(2):293-300. PubMed ID: 21533375
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database.
Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A
Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154
[TBL] [Abstract][Full Text] [Related]
20. Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes.
Yamada H; Sakamoto H; Taira M; Nishimura S; Shimosato Y; Terada M; Sugimura T
Jpn J Cancer Res; 1986 Apr; 77(4):370-5. PubMed ID: 3009377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
